Nu Holdings reported Q1 GAAP EPS of $0.18, below the $0.19 analyst forecast, despite year-over-year growth. Nu Holdings (NU) stock fell 10% in after-hours trading after its first-quarter earnings and revenue fell short of Wall Street expectations. The company posted GAAP e
Gemini Space Station reports stronger-than-expected Q1 earnings and secures a $100M strategic investment from Winklevoss Capital Fund. Gemini Space Station (GEMI) shares climbed after the company posted first-quarter earnings that exceeded market expectations. The crypto a
The company reported a GAAP loss of $0.53 per share, missing estimates by $0.14 amid ongoing capital deployment. Stardust Power reported a first-quarter GAAP loss of $0.53 per share, exceeding the expected loss by $0.14. The company’s net loss widened to $5.2 million for t
The cleantech firm posted a 38-percentage-point year-over-year gross margin improvement despite a wider net loss. 374Water reported Q1 revenue of $551,155, up slightly from $543,100 in the same period last year. Gross margin surged to 63%, or $348,412, compared with 25% in
Trump reported $220m in Q1 2026 financial transactions President Trump disclosed at least $220m in securities transactions involving major US firms. The transactions occurred in Q1 2026 and involved firms such as Microsoft, Nvidia, and Goldman Sachs. Notabl
The childcare provider reported a $0.04 non-GAAP EPS and raised its 2026 revenue outlook to $2.7 billion. KinderCare posted first-quarter non-GAAP earnings per share of $0.04, exceeding expectations by $0.05. Revenue reached $672.52 million, up 0.6% year-over-year and $3.3
The biotech firm reported a wider net loss of $9.0 million for Q1 2025 amid rising operating expenses. Medicus Pharma Ltd. reported a Q1 GAAP loss of $0.31 per share, widening from a prior-year loss as expenses climbed. The company’s net loss totaled $9.0 million, up from
Sky Harbour Group reports a wider-than-expected Q1 loss and revenue miss, despite a 56% year-over-year increase in sales. Sky Harbour Group reported a Q1 GAAP loss of $0.16 per share, missing estimates by $0.03. Revenue reached $8.72 million, up 56% year-over-year but fall
StoneCo reported a 15.4% year-over-year rise in adjusted EPS to R$2.19, exceeding payment volume expectations. StoneCo (STNE) shares climbed 8.03% to $10.43 in post-market trading after first-quarter payment volume surpassed analyst estimates. The company’s adjusted basic
Inhibrx Biosciences posts a Q1 GAAP loss of $2.15 per share as cash reserves rise to $161.7 million. Inhibrx Biosciences reported a first-quarter GAAP loss of $2.15 per share, reflecting ongoing operational costs. The company’s cash and cash equivalents stood at $161.7 mil